SOFIX’S AND A INNOVATIVE PEPTIDE COMBINATION? |

Recent research suggest Sofix’s's Cagrilintide/GLP-1 offers a unique therapeutic approach for targeting glucose-related illnesses. This molecule combination merges Cagrilintide, a targeted GLP-1 receptor stimulator, with a established GLP-1 analogue. The expected synergistic outcome could lead to